Deadline For Changing Liposomal Medicine Names Nears in EU
Executive Summary
EU regulators have explained how makers of medicines with liposomal and pegylated liposomal delivery systems must change the names of their products to avoid medication errors.
You may also be interested in...
EU Revises Liposomal Drug Naming Advice
Marketing authorization holders of liposomal drug delivery systems will have to consider elements such as route of administration, medication error reporting or long-established use to assess whether their medicines are prone to medication errors.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.